(Q35755479)

10 August 2017

title

Imipenem versus moxalactam in the treatment of serious infections (English)

1 reference

10 August 2017

Eron LJ

1

1 reference

10 August 2017

Hixon DL

2

1 reference

10 August 2017

Park CH

3

1 reference

10 August 2017

Goldenberg RI

4

1 reference

10 August 2017

Poretz DM

5

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 December 1983

1 reference

Antimicrobial Agents and Chemotherapy

10 August 2017

published in

1 reference

10 August 2017

volume

24

1 reference

10 August 2017

issue

6

1 reference

10 August 2017

page(s)

841-846

1 reference

Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability

10 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=185393

Susceptibility of the Bacteroides fragilis group in the United States in 1981.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=185393

Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=185393

Ceftazidime therapy of serious bacterial infections

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=185393

Influence of inoculum size on activity of cefoperazone, cefotaxime, moxalactam, piperacillin, and N-formimidoyl thienamycin (MK0787) against Pseudomonas aeruginosa

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=185393

Clinical evaluation of moxalactam: evidence of decreased efficacy in gram-positive aerobic infections

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=185393

Prolonged Bleeding Times and Bleeding Diathesis Associated With Moxalactam Administration

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=185393

Clinical evaluation of moxalactam

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=185393

Clinical experience with Moxalactam in the treatment of pseudomonal and nonpseudomonal infections

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=185393

Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=185393

Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=185393

27 July 2018

Identifiers

DOI

10.1128/AAC.24.6.841

1 reference

10 August 2017

1 reference

10 August 2017

1 reference